Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | ATM serine/threonine kinase | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.003 | 0.2661 | 0.3776 |
Brugia malayi | Phosphatidylinositol 3- and 4-kinase family protein | 0.0022 | 0.0678 | 0.0678 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5929 | 1 |
Trypanosoma cruzi | phosphatidylinositol kinase related protein, putative | 0.0022 | 0.0689 | 0.0052 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.5371 | 0.906 |
Trichomonas vaginalis | PIKK family atypical protein kinase | 0.003 | 0.2661 | 1 |
Schistosoma mansoni | ataxia telangiectasia mutated (atm)-related | 0.0022 | 0.0678 | 0.1144 |
Brugia malayi | Phosphatidylinositol 3- and 4-kinase family protein | 0.003 | 0.2661 | 0.2661 |
Echinococcus multilocularis | FKBP12 rapamycin complex associated protein | 0.0022 | 0.0678 | 0.1144 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.164 | 0.164 |
Schistosoma mansoni | ataxia telangiectasia mutated (atm) | 0.003 | 0.2661 | 0.4488 |
Echinococcus granulosus | serine protein kinase ATM | 0.003 | 0.2661 | 0.4488 |
Trypanosoma brucei | phosphatidylinositol kinase related protein, putative | 0.003 | 0.2661 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.5929 | 1 |
Brugia malayi | Phosphatidylinositol 3- and 4-kinase family protein | 0.0022 | 0.0678 | 0.0678 |
Brugia malayi | hypothetical protein | 0.0043 | 0.5929 | 0.5929 |
Echinococcus granulosus | phosphatidylinositol 3 and 4 kinase | 0.0022 | 0.0678 | 0.1144 |
Giardia lamblia | GTOR | 0.0022 | 0.0678 | 0.5 |
Leishmania major | phosphatidylinositol kinase related protein, putative | 0.0022 | 0.0689 | 1 |
Echinococcus granulosus | FKBP12 rapamycin complex associated protein | 0.0022 | 0.0678 | 0.1144 |
Trypanosoma cruzi | phosphatidylinositol kinase related protein, putative | 0.003 | 0.2661 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.5371 | 0.5371 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5929 | 1 |
Loa Loa (eye worm) | phosphatidylinositol 3 | 0.0022 | 0.0678 | 0.0678 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5929 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.5929 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.5929 | 1 |
Schistosoma mansoni | phosphatidylinositol 3-and 4-kinase | 0.0022 | 0.0678 | 0.1144 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.5371 | 0.5371 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 1 | 1 |
Toxoplasma gondii | FATC domain-containing protein | 0.003 | 0.2661 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.5929 | 1 |
Loa Loa (eye worm) | phosphatidylinositol 3 | 0.0022 | 0.0678 | 0.0678 |
Echinococcus multilocularis | phosphatidylinositol 3 and 4 kinase | 0.0022 | 0.0678 | 0.1144 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.5929 | 1 |
Echinococcus multilocularis | serine protein kinase ATM | 0.003 | 0.2661 | 0.4488 |
Trypanosoma cruzi | phosphatidylinositol kinase related protein, putative | 0.0026 | 0.164 | 0.4849 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 4.1475 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 6.3096 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | = 7.0795 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 16.3601 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 23.1093 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | ||
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.